Image source: The Motley Fool.
AMAG Pharmaceuticals Inc (AMAG)
Q2Â 2019 Earnings Call
Aug. 07, 2019, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good morning. My name is Carmen, and I will be your conference operator today. At this time, I would like to welcome everyone to the AMAG Pharmaceuticals Second Quarter 2019 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]
It is now my pleasure to turn today's program over to Miss. Linda Lennox, Vice President, Investor Relations. You may begin your conference.
Linda Lennox -- Vice President, Investor Relations
Thank you, Carmen. Good morning, and welcome to the AMAG Pharmaceuticals conference call to discuss our second quarter financial results. Earlier this morning, we issued a press release. For those of you who don't have a copy, you can access it in the Investors section of our website at amagpharma.com.
Please be reminded that remarks made during this call may include forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. We want to emphasize that these forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those disclosed in such forward-looking statements. Please refer to our 2018 Form 10-K and our Q1 2019 Form 10-Q for a full review of these risks and uncertainties associated with our business.
On today's call, we will discuss certain non-GAAP financial measures with respect to our performance. We use these non-GAAP measures for financial and operational decision-making and as a mean to evaluate our performance, because we believe they better represent the ongoing economics of our business. The definitions of our non-GAAP measures are set forth in our earnings release, which was filed with the SEC today. Copies may be obtained at sec.gov and in the Investors section of our website.
We have forward-looking estimates of our long-term outlook, including that we will be adjusted EBITDA neutral by 2020. AMAG's growth trajectory and expectations for adjusted EBITDA on a multiyear time frame are based on a strategy of maximizing commercial product opportunities to fund investments in new products with various assumptions, including certain assumptions about the progression and approval of AMAG's product candidates. So please refer to these additional risk factors.
On today's call are Bill Heiden, our President and Chief Executive Officer; Ted Myles, our Chief Financial Officer; and Tony Casciano, our Chief Commercial Officer. Dr. Julie Krop, our Chief Medical Officer will also be with us for the question-and-answer portion on today's call.
Let me quickly run through the agenda for this morning's call. Bill will briefly review the second quarter highlights and some recent developments. Ted will provide an overview of our second quarter financial results and revision to our 2019 financial guidance. Tony will provide an overview of our upcoming launch of Vyleesi, and then Bill will close out the call, and we'll open it up for Q&A.
With that, it's now my pleasure to turn the call over to Bill. Bill?
William K. Heiden -- President and Chief Executive Officer
Thanks, Linda. Good morning, and thanks for joining us on our quarterly update call. We've got a lot to cover this morning, so let's get started.
As we look at the quarter, we saw a strong and consistent execution from our commercial team. This led to sequential and year-over-year revenue and market share growth with subcutaneous Makena auto-injector, Feraheme and Intrarosa. The tables on our press release show the impressive quarter versus same quarter year-ago growth. And on this slide, you can also see that each of our promoted products also grew sequentially versus the first quarter of 2019.
Net revenues for the Makena auto-injector were 8.5% higher than the first quarter, and we saw our market share grow 9 percentage points over the first quarter to 63% market share. Feraheme revenues were up 12% versus the second quarter of last year and up 5% versus Q1. In addition, we achieved record market share of more than 17% in the second quarter. And finally, Intrarosa net revenues were up significantly versus this quarter a year ago and grew 11% over Q1. Total prescription market share grew through the quarter, exiting Q2 at 4.8% market share, our highest share achievement since launch.
Returning to Makena for a moment. There are a couple of other items to report in the quarter that I wanted to touch on right up front. As we mentioned previously, we've had sustained supply disruption with the Makena intramuscular product, stemming for issues that are original contract manufacturer. And we intend to pursue all available remedies against that supplier. These ongoing supply issues caused Prasco to lose market share. And in the face of increased generic competition, we made a mutual decision with Prasco to exit the generic IM market. And Ted will cover the impact in more detail in a few minutes, including the impact on our financial expectations for the year.
As I've already mentioned, Makena auto-injector market share grew to 63%, and we're really proud of that achievement. But based on this share growth, that means that the generic intramuscular market has actually been shrinking and is now less than 40% of the total market. Over the last few months, many of you have asked us about the PROLONG study results and where we go from here with those study results. Today, we also announced that in a recent meeting with the FDA regarding the PROLONG study, the agency informed us that they plan to hold an advisory committee meeting in the fourth quarter of this year to facilitate transparent discussions of the PROLONG trial and allow FDA to obtain the necessary input from advisory committee members, important stakeholders to inform regulatory decision-making from Makena.
While I can't speak to what the FDA will or won't do, I want to reinforce that AMAG continues to firmly believe in the clinical utility of Makena. The original Meis trial run by the National Institutes of Health demonstrate a 30% reduction in the rate of preterm birth in a US patient population compared to placebo. Women at risk of a preterm birth have no other FDA-approved treatment options to lower their risk of preterm birth other than Makena. And preterm births can lead to devastating healthcare outcomes for the newborn.
In addition, preterm birth rates are rising in the United States and are highest in some of the most vulnerable patient populations. We think that the advisory committee is the logical next step as the agency will have an opportunity to hear directly from the Company, clinical experts, medical society representatives and patients on their personal experiences and the scientific data supporting the clinical importance and medical need for Makena. As the meeting draws closer, we'll provide any information that we can, and we look forward to a productive conversation with the FDA and experts about this important medication later this year.
And now, as you know, Vyleesi was approved by the FDA in June. And since that announcement, we've had an incredible amount of media coverage, which has helped raise awareness with potential patients and with medical professionals. More than 300 news outlets across the country, including CNN, Reuters, the LA Times and NBC have covered the Vyleesi approval news. This media pickup has helped drive tens of thousands of visitors to our vyleesi.com website, with approximately half of those visitors taking action, such as answering questions on our symptom checker, see if they might have HSDD or downloading a guide for having a discussion with their physician.
We're currently gearing up for product availability. In just a few weeks, we'll have our national sales force out in the field and we'll also be launching our direct-to-consumer branded digital campaign. Tony will cover some of the details about our upcoming launch and metrics that we'll be watching to gauge early success of the launch a little later on this call.
And with those opening remarks, let me turn the call over to Ted to go through the quarterly financials and our update to full year financial guidance. Ted?
Edward (Ted) Myles -- Executive Vice President, Chief Financial Officer, IR, AMAG Technology & Procurement
Thanks, Bill. Slide 9 shows our revenue by product for the second quarter of 2019 compared to the same period in 2018. The Makena subcu auto-injector continued its strong performance with $41 million of revenue in the second quarter compared to $13 million in the same period last year, which was the auto-injector's first full quarter on the market. We've been very pleased with the success of the auto-injector as we've gained significant share every quarter since launch, even in the face of multiple generic intramuscular competitors.
Next line item illustrates the Makena IM product. Due to the supply disruptions caused by our primary supplier, we were unable to ship any IM product during the quarter. The $10 million in negative revenue reported in the second quarter includes invoices recently received and our estimated remaining liability for Medicaid and commercial rebate obligations for Makena IM from past periods. It is very common to change the estimated liability based on revised assumptions of channel mix, invoice lag and overall exposure, particularly in a heavily Medicaid-oriented market. In some cases, invoices arrive many quarters after the initial sale of the product. This new information is incorporated in our current reporting and future expectations.
Once again, Feraheme demonstrated strong performance in the quarter with revenue of over $42 million. This growth was all driven by volume. Not only did the IV iron market grow during the quarter, but so did Feraheme's share of that market. Our Heme/Onc team continues to deliver strong results, and we believe Feraheme will continue to be a source of steady cash flow.
Second quarter sales of Intrarosa were $4.9 million, up from $3.2 million in the same period last year. As you recall, we made a couple of changes to the patient copay savings program in the first quarter of this year, and believe we have optimized that program. As Bill showed, we are back on a steady NRx and TRx growth trajectory.
Moving down, the P&L on the next slide presents operating expenses and operating results on a GAAP and non-GAAP basis for the second quarter of 2019 compared to the same period in 2018. We broke out a couple of line items to better illustrate the trends driving our results for the period. Cost of product sales includes amortization of intangible assets. During the second quarter of 2018, we recognized approximately $61 million of amortization expense, substantially all of this was related to the Makena IM product. During the second quarter of 2019, we didn't recognize any Makena IM amortization, because we did not sell any Makena IM product. The Q2 2019 direct cost of product sales includes a $4.8 million write down of Makena intramuscular inventory.
R&D and SG&A were aligned with our expectations. The [Indecipherable] of the SG&A line item is a bit complicated by the 2018 reversal of approximately $50 million of contingent liability. During that period, we determined that it was unlikely that we will achieve a sales milestone that would have triggered a payment to the former Lumara shareholders and therefore, we reversed the liability and recorded a negative expense.
Late in the second quarter of 2019, we determined that it was probable that we would no longer supply Prasco and therefore, our revenue forecast for intramuscular product was revised to zero. This resulted in a full impairment of the Makena IM intangible asset, a non-cash charge in the second quarter of 2019 of $77 million. During the second quarter, we recorded a loss in adjusted EBITDA of approximately $24 million. This is higher than expected, largely driven by lost sales and negative revenue of the intramuscular products.
So as we review our expectations for the full year, we have decided to lower our financial guidance for 2019, due to the loss of revenue from the Makena intramuscular product and our ciraparantag development partner informing us they intend to terminate our agreement. While we believe they have no grounds for termination, we've removed the milestone revenue from our 2019 expectations. You can see on the left side of the slide that for the six months ended June 30, 2019, we reported revenue of approximately $154 million and adjusted EBITDA loss of approximately $50 million.
Our revised guidance on the far right of the slide, revenue of $340 million and adjusted EBITDA loss of $80 million at the respective midpoints, assumes no IM revenue and the removal of approximately $20 million of previously expected milestone revenue. Our operating plan for the back half of the year is based on continued strong commercial performance of the Makena subcu auto-injector and continued growth of Feraheme and Intrarosa and also includes continued investments in the development of ciraparantag and AMAG-423 in a fully funded launch plan for Vyleesi.
Moving to the balance sheet. We believe our products and portfolio are important opportunities to address unmet medical needs for patients and are worthy of these near-term investments. The work we have done to transform our balance sheet over the past several years, early retirement of more than $1 billion in debt, has positioned us to make these investments and even go into a temporary loss position in 2019.
As we look to the back half of 2019, as a period of narrowing our adjusted EBITDA loss versus the first half of the year, thereby setting up adjusted EBITDA neutral 2020. We ended the second quarter with $261 million of cash. In July, we made the $60 million milestone payment to Palatin.
Tony is now going to provide an overview of our upcoming launch of Vyleesi. Tony?
Tony Casciano -- Chief Commercial Officer
Thanks, Ted. And good morning, everyone. I'd like to take just a couple of minutes to provide a few updates on Vyleesi, including early market signals and elements of our national launch scheduled for September. The AMAG team is very excited to bring this product to market. We know from market research that approximately one in 10 premenopausal women experience symptoms of HSDD. Yet, most of these women do not realize they are experiencing a treatable medical condition. We also believe from our own market research that Vyleesi has the potential to raise awareness by providing a safe and effective new treatment option to an undeserved patient population with acquired, generalized HSDD.
Our very early assessment of the market post approval would suggest we're not the only one, who's excited by changing the way HSDD is discussed and treated. To date, we've seen over 500,000 visitors to our unbranded patient website, unblush.com, or visited or staying longer and viewing more content than we typically see on unbranded sites. This time is translating into actions with over 80,000 visitors have been completed HSDD symptom checker to-date.
In mid-July, we rolled out our early experience program. This is a targeted program designed to help us learn more about the market. We have 20 sales reps in the field today, calling on a small subset of healthcare providers across the country. Their feedback is helping us validate and challenge our assumptions from research on the treatment of HSDD, which is further informing our targeting and messaging. We'll use these insights and feedback to refine and improve our plans ahead of launch.
As mentioned, our national launch will take place in September with the activation of our high-performing and fully trained sales force of approximately 125 sales representatives. These are the sales professionals who are currently promoting Intrarosa and the Makena auto-injector. This team will be following on approximately 15,000 healthcare professionals at launch, consisting mostly of OB/GYNs, but will also include sexual medicine specialists and select primary care offices.
As we shared before, we're committed to helping ensure premenopausal women with acquired, generalized HSDD have access to Vyleesi. Over the past couple of months, our market access team has been working hard to educate payers on the clinical profile of Vyleesi. We recently submitted our listing to the compendia, which will now put Vyleesi in the national electronic pharmacy ordering system and payer processing systems.
We believe that Vyleesi will eventually reach the same broad commercial coverage as seen with other approved sexual health products, which our research would indicate is currently in the 60% to 70% range of all commercial insurance plans. As you probably anticipate, we expect the price for Vyleesi will vary by patient's insurance. And like most newly approved products, we expect payer access will take time. In the meantime, we're making the first four pack of Vyleesi available to patients for a $0 copay on our first prescription and a maximum of $99 on our subsequent refills of the four pack.
To help ensure a positive experience for patients, we will be launching Vyleesi through two specialty pharmacies. We believe the discrete nature of home delivery coupled with services provided by this type of model will be well received by our target patient demographic.
So I'll close on how I started by emphasizing the excitement at team AMAG for Vyleesi. This is an important moment as we bring the first FDA-approved as-needed treatment option to the millions of premenopausal women with acquired, generalized HSDD and to the physicians who are treating them.
Vyleesi is an innovative product. We want to provide women and healthcare providers with an experience to match. This starts by driving awareness of HSDD, helping faster conversations between patients and physicians and ultimately differentiating Vyleesi in the marketplace. Our commercial organization is already hard at work to deliver a successful launch in September.
And with that, I'll turn it back over to Bill for closing remarks. Bill?
William K. Heiden -- President and Chief Executive Officer
Thanks, Tony. Well, as you just heard, this is an important moment for patients and our Company. Only two years ago, when we had just two commercial products, we set the ambitious goal to bring even more innovative treatments to patients, to expand our product portfolio and to build additional durable revenue streams. We set out to in-license or acquire late-stage development medicines and take them through to regulatory approval. And we have done just that.
We have been building additional internal capabilities to support this goal and recent regulatory approvals for Feraheme broad label and Makena subcutaneous auto-injector. And just this past quarter, the approval of Vyleesi show that we are successfully executing on the strategy.
And today, we have two other exciting development programs, AMAG-423 and ciraparantag. AMAG-423 is a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women. There are currently no FDA-approved treatment options for severe preeclampsia and it is the leading cause of maternal and neonatal mortality. Enrollment in clinical trials for this condition is challenging and as such, difficult to predict on the timing of enrollment completion. We are continuing to add new sites and enroll additional patients in this Phase 2a/3b trial for AMAG-423.
Ciraparantag is our other development program. Ciraparantag is in development as a single dose, ready-to-use solution for patients treated with novel oral anticoagulants or low-molecular-weight heparin when reversal of the anticoagulant effect is needed for emergency surgery or serious uncontrolled bleeding.
We and our partners from Perosphere Technology recently met with the FDA to discuss the upcoming submission of an IDE, or an investigational device exemption, for the automated coagulometer. Based on approval of that IDE submission, we expect to initiate a Phase 3a program for ciraparantag in the fourth quarter of this year. We had considered pursuing a breakthrough designation for ciraparantag. But based on feedback from the agency on additional data that might be required to achieve breakthrough, we've decided not to pursue that application. Ciraparantag already has fast track designation, which will allow us to apply for an expedited review at our NDA filing.
Investments in the launch of Vyleesi and our development-stage products will allow AMAG to bring additional innovative therapies to patients in need and build a new chapter of durable growth for shareholders.
And with that, we'll conclude our prepared remarks, and we will open the call for questions. Carmen?
Questions and Answers:
Operator
Certainly. [Operator Instructions] And your first question comes from the line of Daniel[Phonetic] Tsao with H.C. Wainwright. Douglas, your line is open.
Doug Tsao -- H.C. Wainwright -- Analyst
Hi, good morning. Thanks for taking the question. Just as a starting point, in terms of the FDA Ad Comm that's upcoming, have you been engaged in conversations with any of the key medical societies in terms of ACOG to get their perspective on the results from prolonged and -- in anticipation of what they might sort of discuss at this meeting?
William K. Heiden -- President and Chief Executive Officer
Thanks, Doug. I'm going to ask Julie. Julie Krop, our Chief Medical Officer, is here and I'm going to ask her to answer that question for you.
Julie Krop -- Executive Vice President, Chief Medical Officer
Yes. Hi, of course, it's critical. And I think the FDA in asking for this Ad Comm is very interested in understanding sort of the totality of the data from a variety of different stakeholders, obviously including the medical societies. And yes, of course, we are in -- constantly are in contact with them and we'll continue to provide them with all the information they need in order to be able to access participants in this whole discussion at the advisory committee.
William K. Heiden -- President and Chief Executive Officer
Yes. They're obviously an important stakeholder, Doug. They treat these patients. They are aware that this is the only treatment option for patients who are at risk of a preterm birth, so they have a lot of stake here. And Julie and her team have been working closely, so they will definitely play a role at the advisory committee.
Doug Tsao -- H.C. Wainwright -- Analyst
And maybe could you share some of just the early feedback that you've gotten from them in terms of the results from -- of PROLONG?
Julie Krop -- Executive Vice President, Chief Medical Officer
Yes. I mean, I really can't speak for the medical societies. I mean, I think we had AMAG -- as Bill reiterated, I mean, this is a unique situation. This is product has been on the market for over 50 years, obviously, widely used by physicians. It's in the guideline for ACOG and SMFM for treatment of patients with prior preterm birth. Strong safety profile. Obviously, the recent PROLONG data reinforce that. And I think we're just in a unique situation with prior US positive data and now a negative trial in patients outside the US with a different healthcare system and a different set of risk factors on patients treated in the US. And so such totality of the data is all that we can put together to try to understand how this will be handled. And I think that -- as I said, I just can't speak for how the medical societies will respond because that -- we can't speak for them. So...
Doug Tsao -- H.C. Wainwright -- Analyst
Okay. And then just one quick one. Jumping between calls this morning, so I might have missed it. But just in terms of the termination of the collaboration agreement on ciraparantag, just what that means in terms of the time lines and development and even just the future of the program for AMAG? Thanks.
William K. Heiden -- President and Chief Executive Officer
Yes. So the -- I mean, this is the background, I think to the termination, this is a partner that actually did not end up having a significant stake in the US anticoagulant market. This was a US co-development agreement. And so certainly, background is understandable. From a contractual standpoint, we don't believe that the partner actually has the ability to terminate. So we think, ultimately, we will prevail, but -- the most conservative course was to remove it from our financial guidance. The development plan is really unchanged. We are developing this product in combination for use with the various anticoagulants and low-molecular-weight heparin, but it does not change the development plans.
Julie, any further comments?
Julie Krop -- Executive Vice President, Chief Medical Officer
Yes. No. And it doesn't -- it also doesn't change our time line. Our time lines were not dependent on the agreement.
Doug Tsao -- H.C. Wainwright -- Analyst
Okay. Thank you, very much.
William K. Heiden -- President and Chief Executive Officer
Okay. Thanks, Doug.
Operator
And your next question is from the line of Jessica Fye with JPMorgan.
Jessica Fye -- JPMorgan -- Analyst
Hey, guys. Good morning, and thanks for taking my questions. First on guidance, I appreciate you reiterating the guidance for 2020 to be neutral on an adjusted EBITDA basis. When we think about the roughly $80 million year-over-year improvement you're projecting, can you help us think about how much of that will come from higher revenue versus lower OpEx? I asked because consensus has your 2020 revenue up about $10 million year-over-year, suggesting the rest would need to come from expense cuts, assuming consensus is close.
Edward (Ted) Myles -- Executive Vice President, Chief Financial Officer, IR, AMAG Technology & Procurement
Hey, Jess, it's Ted here. So it's a little early to talk specifically about our next year expectations, but we see a lot of stability in the portfolio. Obviously, 2020 EBITDA neutral assumes continued great execution on Makena subcu, Feraheme. Intrarosa will -- clearly by the end of the year will be in cash flow positive bucket with Makena and with Feraheme. And then there's a bit of -- as you know, 2019 was a big R&D year and a two launch -- two-product launch year. As we get into 2020, we're still driving the Vyleesi launch, but less so on Intrarosa, because we're out of launch mode there. And we believe a lot of the R&D costs that aren't being incurred in 2019 will may begin in 2020.
Jessica Fye -- JPMorgan -- Analyst
Okay. Got it. And just sticking with guidance, with the 2019 revenue guidance coming in, not fully explained by I think the $20 million ciraparantag milestone that was supposed to come in this year, is the rest from Makena IM? And are you standing by the $40 million to $50 million quarterly run rate from Makena with solely the subcu product?
Edward (Ted) Myles -- Executive Vice President, Chief Financial Officer, IR, AMAG Technology & Procurement
Yes. So the big drivers of the guidance lowering were clearly, as you said, Makena IM. As you know, we had -- so $10 million of negative revenue in Q2. There were some headwinds in Q1. So not only that we're recounting on positive revenue for the Makena with particularly the generic IM product, who are authorizing our partnership, but we actually incurred negative revenue. So that's a bit of a hole. So that's a key driver, and then the -- what we'll call the conservative removal of the $20 million of ciraparantag development milestone revenue. Those two drove the guidance revision.
And your other question about $40 million to $50 million of Makena, we've talked about that sort of big picture and largely driven by the subcu. We're really proud of the results in Q2. The subcu delivered $41 million of revenue. So we're in that range, and we're continually encouraged by the progress the commercial team is making with the subcu and the adoption by physicians.
William K. Heiden -- President and Chief Executive Officer
Yes. If you think about the go forward now, Jess, the -- this is Bill. Obviously, the share that we've achieved for the full quarter, 63%, for the auto-injector is performing very, very nicely. The intramuscular market has been shrinking over the last several quarters. And so as we look to the future, sort of -- we eventually were likely going to get out of the intramuscular market any way as multiple players came into that market and became sort of less interesting, if you will, but the success of the Makena auto-injector is really what's going to drive revenues going forward.
Jessica Fye -- JPMorgan -- Analyst
Okay. Got it. And just last one following up on the prior question on ciraparantag. Can you help us understand like what Daiichi was asserting to be able to terminate the agreement? And remind me when you believe you could report the Phase 3a results for that product?
Edward (Ted) Myles -- Executive Vice President, Chief Financial Officer, IR, AMAG Technology & Procurement
Sure. So I don't want to get into the specifics of what Daiichi is asserting because then we get into legal contractual language and so I don't want to get into that. Again, you can certainly understand, from a commercial perspective, they don't have a presence in the US market. And so I certainly understand there may be some background where you could understand why they might want to try and get out of this agreement, but we think contractually, they actually don't have the ability to do so.
In terms of timing, let me turn it over to Julie.
Julie Krop -- Executive Vice President, Chief Medical Officer
Yes. So I don't have the exact timing today, but probably -- definitely sometime in the first half of next year we'll be able to report that data for the Phase 3a study.
Edward (Ted) Myles -- Executive Vice President, Chief Financial Officer, IR, AMAG Technology & Procurement
And fortunately, these trails are pretty fast...
Julie Krop -- Executive Vice President, Chief Medical Officer
Yes. They're pretty fast. I mean, as you remember, healthy volunteer studies. So yes, it's pretty quick. So...
Jessica Fye -- JPMorgan -- Analyst
Okay, great. Thank you.
Edward (Ted) Myles -- Executive Vice President, Chief Financial Officer, IR, AMAG Technology & Procurement
Thank you, Jess.
Operator
And your next question comes from the line of Ami Fadia with SVB Leerink. Please go ahead.
Unidentified Speaker --
Thank you guys.
Operator
All right. Your next question comes from the line of Amy Faria with SVP Leerink. Please go ahead.
Eason Lee -- SVB Leerink -- Analyst
Hi, good morning. This is Eason on for Ami. Thank you for taking our questions. Maybe first, I think you sort of touched on this, Bill, but just wanted to confirm. So the fact that you didn't change sort of your preliminary view of 2020 despite the lowering of 2019 guidance, it sounds like you didn't assume -- basically that the IM has pretty negligible contribution in 2020. Just wanted to sort of confirm that if that's the case.
William K. Heiden -- President and Chief Executive Officer
Yes. That's right, Eason. And again, the subcu auto-injector is performing as well or better than we had expected. And so interesting versus our forecast from a year or two ago, the intramuscular market is shrinking. And so as uninteresting as that market was forecasted to be is becoming even less interesting as it continues to get smaller. There are other generics that have entered the market. And so rather than be a contributor with our authorized generic to being another player in that market and as complicated by the supply challenges that we've had with the intramuscular, we decided the best course going forward was to focus on the continued execution and great success we've had with the subcutaneous auto-injector.
Eason Lee -- SVB Leerink -- Analyst
Okay. And then, maybe I guess focusing on the rest of the year, just on sort of generic IMs, there seem to be one that's -- that has been picking up share pretty recently. Maybe could you just sort of give us maybe more -- like more broadly sort of your expectations in terms of number of generics for the rest of the year? And then also in terms of your sort of AG contribution, I think we still see some scripts, obviously, flowing from Prasco into the third quarter. Will there be any sort of financial impact in failure to supply penalty that sort of kicks-in in third quarter? Maybe just -- maybe help us just work through the numbers there. Thank you.
William K. Heiden -- President and Chief Executive Officer
Okay. So let me start with just a big comment, which is I think some of the analyst community is actually buying a different data set than we buy. So we have very accurate data on the market. And so as I mentioned, the intramuscular market is shrinking. Now there are some folks trading share within that market, but important to keep in mind that the market is actually getting smaller. In terms of the financial impact, Ted, maybe you want to mention...
Edward (Ted) Myles -- Executive Vice President, Chief Financial Officer, IR, AMAG Technology & Procurement
Yes. So we are seeing some Prasco shipments currently that make sense. We didn't ship any product to Prasco in Q2 or Q3 for that matter. They still hold -- they may still hold some inventory and we are putting that out in the market based on their own demand.
William K. Heiden -- President and Chief Executive Officer
Actually, we've already booked those revenues in Q1...
Edward (Ted) Myles -- Executive Vice President, Chief Financial Officer, IR, AMAG Technology & Procurement
Yes. So there's minimal financial exposure to us -- there is a small amount of inventory and minimal exposure.
William K. Heiden -- President and Chief Executive Officer
Yes. The expectation is they will continue to bleed out that inventory and ultimately deplete the inventory that they have on hand. Tony, anything further?
Tony Casciano -- Chief Commercial Officer
No. Just a comment maybe, a question was asked on a number of generics. So we see a number of them today. I think Bill added on, as there's some horse trading going on, we focus on the big number, which is total generic uptake versus branded subcutaneous auto-injector, that's moving in the right way. We would expect more generics simply because we know there's at least a couple more out there with file sitting with the FDA. But from a generic perspective today, we think the market is fully supplied. There's enough of amount here, so we're starting to see what we believe are kind of two discrete markets out there.
Eason Lee -- SVB Leerink -- Analyst
Okay. Thank you very much.
William K. Heiden -- President and Chief Executive Officer
Thanks, Eason.
Unidentified Speaker --
Thanks, Eason.
Operator
Your next question comes from the line of Serge Belanger with Needham.
Serge Belanger -- Needham -- Analyst
Hi, good morning. Thanks for taking my question. I guess first on Makena. Can you just talk whether the supply issues that are affecting the intramuscular product can have any carryover to the auto-injector going forward?
William K. Heiden -- President and Chief Executive Officer
Yes. No, they don't. There are two separate suppliers and this whole intramuscular supply issue really was caused by one supplier, our primary supplier in the intramuscular form. And again, they have nothing to do with the subcu auto-injector.
Serge Belanger -- Needham -- Analyst
Okay. And then on ciraparantag, just remind us what kind of collaboration structure was in place. And now that it's being terminated, whether you will seek an additional partner for development?
William K. Heiden -- President and Chief Executive Officer
So the development partnership was really funding based on the development of our reversal agent in combination with a particular oral anticoagulant. And so, as I said, whether that's in or out, frankly, does not change our development plan or program at all.
In terms of additional development partner, certainly not the way this program was structured. There is interest in partnering ciraparantag ex-US and so there may be eventually some type of partnership that's consummated around ciraparantag ex-US, but I don't see a replacement development program that's structured the same way this current development program is structured with Daiichi Sankyo.
Does that answer your question, Serge?
Serge Belanger -- Needham -- Analyst
Yes. And then one last one on Vyleesi. I guess what kind of commercial coverage you expect to launch in September? And how should we think about lack in that pricing progression this year or next year?
Tony Casciano -- Chief Commercial Officer
Yes. Sure. So thanks for the question. So super early to be putting targets out there for coverage as they did in the forward comments, I think. We do anticipate eventually we'll get the level seeing with other therapies out in the marketplace today of roughly 60% to 70%, but Vyleesi is a one-of-a-kind product. We're just now going to go back and start having discussions with payers. We've now the lack price listed. And we'll kind of let you know as you go forward. We've got high expectations for coverage over time, but it's early to say just when and how that kind of takes forms.
William K. Heiden -- President and Chief Executive Officer
Yes. Just want to restate, Tony, the patient access program...
Tony Casciano -- Chief Commercial Officer
Yes, [Indecipherable] I apologize. And I know -- some folks are jumping on the call midway and late, so maybe I'll just restate for the benefit of the folks that maybe joining later in the call. So even though we do anticipate that type of coverage, we do anticipate -- like I said, it's going to take some time. In the interim, we believe access to the product is critical at launch, so we will be launching with $0 copay for first fill of the four pack and then a $99 max out-of-pocket for patients for subsequent refills of the four pack.
William K. Heiden -- President and Chief Executive Officer
So I think what you'll see, Serge, is not uncommon right into the product launch. You'll see a relatively high growth -- just at the start and then that will come down over time and net price will go up over time based on coverage.
Serge Belanger -- Needham -- Analyst
Great, thank you.
William K. Heiden -- President and Chief Executive Officer
Thank you, Serge.
Operator
Your next question comes from the line of Tyler Knisley with SunTrust.
Tyler Knisley -- SunTrust -- Analyst
Hi, this is Tyler on for Greg. Thanks for taking the questions. I just have one quick one on Makena. Do you think that the recent court ruling on the compounding vasopressin could have any implications for the Makena market?
William K. Heiden -- President and Chief Executive Officer
No. I don't think so. Because when you think of -- obviously we've got generics which are lower-priced versions -- a lesser version, if you will, in intramuscular form versus the subcutaneous auto-injector, but I think today there is a low-priced option. And -- so I don't think that we're going to reopen that Pandora's box of exposing patients to compounded hydroxyprogesterone caproate, because of the availability of generic. So no, I don't think that has any impact.
Tyler Knisley -- SunTrust -- Analyst
Okay, thank you.
William K. Heiden -- President and Chief Executive Officer
Okay. Thanks Tyler.
Operator
There are no other questions at this time. I will now turn the call back over to Bill Heiden for any closing remarks.
William K. Heiden -- President and Chief Executive Officer
Great. Thank you, Carmen, and I want to thank everybody for joining us on the call today. We have got a busy Q3 in front of us, and we look forward to updating you on our continued progress that busy Q3 includes the launch of Vyleesi, which is really just a few weeks away. So we're all very enthusiastic to get that out into the marketplace and help even more patients. So thank you, again, for your time, and we look forward to continuing to update you on our progress.
[Operator Closing Remarks]
Duration: 41 minutes
Call participants:
Linda Lennox -- Vice President, Investor Relations
William K. Heiden -- President and Chief Executive Officer
Edward (Ted) Myles -- Executive Vice President, Chief Financial Officer, IR, AMAG Technology & Procurement
Tony Casciano -- Chief Commercial Officer
Doug Tsao -- H.C. Wainwright -- Analyst
Julie Krop -- Executive Vice President, Chief Medical Officer
Jessica Fye -- JPMorgan -- Analyst
Unidentified Speaker --
Eason Lee -- SVB Leerink -- Analyst
Serge Belanger -- Needham -- Analyst
Tyler Knisley -- SunTrust -- Analyst
Transcript powered by AlphaStreet
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
